The obstacle to developing such therapeutics is the unconventional structure of nucleic acid-binding domains in these proteins. Unlike the enclosed binding pockets of enzymes or receptor active sites, nucleic acid-binding domains have convex, exposed, and highly positively charged interfaces. These properties complicate the development of small-molecule inhibitors of nucleic acid-binding proteins. For this reason, these proteins have long been deemed 'undruggable'.